Skip to content

The Effect of Semantic Support on Word Learning

Identification of Treatment Parameters That Maximize Language Treatment Efficacy For Children

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05921214
Enrollment
32
Registered
2023-06-27
Start date
2025-06-10
Completion date
2026-12-01
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Language Development Disorders

Keywords

Late Talkers

Brief summary

The goal of this clinical trial is to compare word learning outcomes in late talking toddlers who are taught different types of words. The main question it aims to answer is if teaching words that come from categories that children already know (e.g., animals) will aid overall word learning. Children will take part in the Vocabulary Acquisition and Usage for Late Talkers (VAULT) word learning treatment and be taught words from more familiar or less familiar categories to see which group learns more words overall.

Detailed description

Children will be assigned to either the familiar or less-familiar word group. All children will receive 8 weeks of Vocabulary Acquisition and Usage for Late Talkers (VAULT) word learning treatment (2x/wk for 30 minutes each session). The investigators will measure how well children learn the words they are taught as well as the words that are in the environment, but not explicitly taught (control words). This will help us know if their learning is due to treatment or maturation. The investigators will compare children to themselves (taught words v. control words) to ensure that the overall treatment is working. Then, the investigators will compare children in the familiar word group to children in the less-familiar word group to see which group learns more overall.

Interventions

BEHAVIORALVAULT Phase 5

This is an input-based vocabulary learning treatment based on principles of statistical learning.

Sponsors

University of Arizona
Lead SponsorOTHER
National Institute on Deafness and Other Communication Disorders (NIDCD)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Masking description

The late talkers and their caregivers will not explicitly be told what condition their child is in.

Intervention model description

Using treatment effect sizes, children will be compared to themselves (treatment words v. control words) and across groups (familiar word group v. less-familiar word group).

Eligibility

Sex/Gender
ALL
Age
2 Years to 4 Years
Healthy volunteers
No

Inclusion criteria

* Native English Speaking * Pass pure tone hearing screening or medical report of normal hearing * 2-3 Years of age * MCDI expressive scale \<10th percentile

Exclusion criteria

* Parental report of other diagnoses * Enrolled in concurrent treatment elsewhere * Nonverbal IQ \<75 as measured by the Bayley scales * Parents unable to consistently bring child to treatment sessions

Design outcomes

Primary

MeasureTime frameDescription
Treatment Effect SizeChange from baseline through treatment, which will average an 8-week time frame.The investigators will count the number of spontaneous and probed productions of target and control words and calculate a treatment effect size (d).
Number/Rate of Words LearnedChange from Initial Evaluation through Follow-up, which will average a 6-month time frame.The investigators will measure the number of words learned and rate of words learned as reported by the parent on the MCDI starting prior to treatment, and measured during, immediately following, and 4-6 weeks after treatment.

Secondary

MeasureTime frameDescription
Post Treatment RetentionChange from end of treatment to follow up, which will average 4-6 weeks.The investigators will use probe data and parental report to determine how many words the child retained from treatment.

Countries

United States

Contacts

CONTACTMary Alt, PhD
malt@arizona.edu520-626-6180
CONTACTNora Evans-Reitz, MS
nevansreitz@arizona.edu520-626-6885
PRINCIPAL_INVESTIGATORMary Alt, PhD

University of Arizona

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026